IRIS
CASCINU, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.022
NA - Nord America 3.918
EU - Europa 2.975
SA - Sud America 2.168
AF - Africa 138
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 5
AN - Antartide 1
Totale 15.242
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.735
SG - Singapore 2.404
BR - Brasile 1.815
CN - Cina 1.567
HK - Hong Kong 952
SE - Svezia 782
VN - Vietnam 631
RO - Romania 549
IT - Italia 461
RU - Federazione Russa 364
DE - Germania 249
AR - Argentina 153
FI - Finlandia 113
GB - Regno Unito 109
IN - India 93
CA - Canada 74
MX - Messico 73
ID - Indonesia 67
BD - Bangladesh 64
AT - Austria 62
EC - Ecuador 60
ZA - Sudafrica 58
PL - Polonia 53
NL - Olanda 48
ES - Italia 45
JP - Giappone 42
CO - Colombia 37
TR - Turchia 35
FR - Francia 34
IQ - Iraq 33
IE - Irlanda 28
CL - Cile 24
PY - Paraguay 24
VE - Venezuela 23
UA - Ucraina 22
MA - Marocco 21
UZ - Uzbekistan 19
EG - Egitto 17
PK - Pakistan 17
IR - Iran 16
LT - Lituania 15
UY - Uruguay 15
PE - Perù 13
AE - Emirati Arabi Uniti 12
KE - Kenya 11
AZ - Azerbaigian 10
TN - Tunisia 10
AL - Albania 9
EU - Europa 9
IL - Israele 8
BY - Bielorussia 7
KZ - Kazakistan 7
SA - Arabia Saudita 7
HN - Honduras 6
OM - Oman 6
AO - Angola 5
AU - Australia 5
BE - Belgio 5
DZ - Algeria 5
JM - Giamaica 5
NP - Nepal 5
BO - Bolivia 4
LB - Libano 4
PA - Panama 4
XK - ???statistics.table.value.countryCode.XK??? 4
BB - Barbados 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
KW - Kuwait 3
MY - Malesia 3
NI - Nicaragua 3
PH - Filippine 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
A1 - Anonimo 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
GA - Gabon 2
GE - Georgia 2
HR - Croazia 2
KG - Kirghizistan 2
MN - Mongolia 2
PR - Porto Rico 2
PS - Palestinian Territory 2
RS - Serbia 2
SC - Seychelles 2
SN - Senegal 2
TW - Taiwan 2
AQ - Antartide 1
BM - Bermuda 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DM - Dominica 1
GT - Guatemala 1
HU - Ungheria 1
JO - Giordania 1
KR - Corea 1
Totale 15.235
Salva come PNG Salva come JPEG
Città #
Dallas 1.256
Singapore 1.043
Hong Kong 950
Ashburn 386
Shanghai 383
Hefei 366
Lawrence 314
Princeton 313
Ho Chi Minh City 266
Beijing 246
New York 200
São Paulo 167
Moscow 141
Los Angeles 129
Hanoi 110
Helsinki 93
Milan 85
Boardman 71
Nuremberg 68
Munich 66
Rio de Janeiro 56
Warsaw 49
Rome 40
Tokyo 38
Belo Horizonte 35
Guangzhou 33
Haiphong 33
Stockholm 33
Cesano Boscone 32
Brasília 31
Poplar 31
Denver 30
Vienna 30
Brooklyn 29
Orem 29
Johannesburg 28
Montreal 28
Chicago 27
Dublin 27
Porto Alegre 27
Santa Clara 26
The Dalles 25
London 24
Campinas 23
Chennai 23
Curitiba 23
Guayaquil 22
Houston 22
Da Nang 21
Ribeirão Preto 21
Guarulhos 20
Boston 19
Mexico City 19
Toronto 19
Ankara 18
Columbus 18
Quito 18
Tashkent 18
Thái Bình 18
Amsterdam 17
Biên Hòa 17
Atlanta 16
Phoenix 16
Salvador 16
Buenos Aires 15
Hortolândia 14
Montevideo 14
Recife 14
Turku 14
Blumenau 13
Dhaka 13
Frankfurt am Main 13
Manchester 13
Tianjin 13
Contagem 12
Hải Dương 12
Manaus 12
Mumbai 12
Querétaro 12
Brescia 11
Duque de Caxias 11
Fortaleza 11
Nairobi 11
Niterói 11
Seattle 11
Sumaré 11
Volta Redonda 11
Washington 11
Xi'an 11
Baghdad 10
Cape Town 10
Ha Long 10
Lima 10
Pelotas 10
Romagnano Sesia 10
Shenzhen 10
Asunción 9
Baku 9
Carapicuíba 9
Franca 9
Totale 8.210
Salva come PNG Salva come JPEG
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 388
Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines 380
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 373
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 315
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 112
DIET AND LIFESTYLE HABITS IN EARLY-ONSET COLORECTAL CANCER. A PILOT CASE-CONTROL STUDY 85
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel 82
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 81
Advanced Digestive Neuroendocrine Tumors Metastatic Pattern Is an Independent Factor Affecting Clinical Outcome 81
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe 80
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 80
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study 78
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 78
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients 77
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 75
Early integration of palliative care in oncology practice: Results of the Italian Association of Medical Oncology (AIOM) survey 73
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 72
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes 71
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 71
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors 70
Does immunotherapy change the treatment paradigm in metastatic gastric cancer? 68
Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy: A systematic review on current evidences and predicting factors 68
Emergency Department Visits among Cancer Patients during SARS-CoV-2 Pandemic 67
Metabolism and immune modulation in patients with solid tumors: Systematic review of preclinical and clinical evidence 67
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 66
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 66
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor 66
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 65
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 65
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives 65
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 65
Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial 64
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer 64
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma 63
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 63
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients 63
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients 63
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 62
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX 62
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 62
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 61
Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma 61
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 61
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma 61
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study 60
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 59
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 59
5-Fluorouracil pharmacogenomics: still rocking after all these years? 59
Prediction of early distant recurrence in upfront resectable pancreatic adenocarcinoma: A multidisciplinary, machine learning-based approach 59
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 59
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW 58
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 57
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 57
Cholangiocarcinoma: new perspectives for new horizons 56
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients 56
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 56
Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC) 55
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 55
The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial 54
BRAF-mutated colorectal cancer: Clinical and molecular insights 54
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 54
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients 53
Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time? 53
Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life 52
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 51
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study 51
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 51
To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer 51
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery 51
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 50
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication 50
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 50
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 49
The Italian Rare Pancreatic Exocrine Cancer Initiative 49
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 49
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 48
Is there a role for chemotherapy after local relapse in high-grade osteosarcoma? 48
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 47
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 47
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial 47
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 47
The prognostic value of the new combined hemo-eosinophil inflammation index (Hei index): A multicenter analysis of anal cancer patients treated with concurrent chemo-radiation 47
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer 46
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 46
Evolution of surgical treatment of colorectal liver metastases in the real world: Single center experience in 1212 cases 46
Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review 46
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 45
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib 45
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 44
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 44
Dabrafenib-trametinib combination in 'field-practice': An Italian experience 44
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 44
Atezolizumab and bevacizumab in advanced HCC: ready for prime time? 44
Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity 44
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study 44
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 43
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 43
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 43
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients 43
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 43
Totale 7.065
Salva come PNG Salva come JPEG
Categoria #
all - tutte 127.681
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 127.681
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021264 0 0 0 0 0 131 41 91 0 0 1 0
2021/2022229 0 1 0 99 7 7 23 43 19 7 6 17
2022/20231.524 736 283 86 8 13 201 41 73 59 6 10 8
2023/2024684 23 38 88 84 43 148 11 61 9 28 46 105
2024/20255.225 624 116 62 58 94 428 1.072 461 832 777 306 395
2025/20267.808 1.109 1.513 1.457 2.205 1.133 391 0 0 0 0 0 0
Totale 15.741